Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3+CD8+ T cells against Various Solid Tumors

Jooeun Bae^1,2*, Derin B Keskin^1,2, Kristen Cowens^1,2, Ann-Hwee Lee³, Glen Dranoff^1,2, Nikhil C Munshi^1,2,4 and Kenneth C Anderson^1,2

¹Dana-Farber Cancer Institute, Boston, Massachusetts, USA

²Harvard Medical School, Boston, Massachusetts, USA

³Weill Cornell Medical College, New York, NY, USA

⁴VA Boston Healthcare System, Boston, Massachusetts, USA

^*Corresponding Author: Jooeun Bae, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA, Tel: 617-632-5908, Fax: +617-632-2140 Email: